This Month in JNM

Updated SSR imaging guideline: Balon offers background and perspective on the revised version of the SNM Practice Guideline for Somatostatin Receptor Scintigraphy that appears this month in the Journal of Nuclear Medicine Technology.Page 1838

Toward clinical Raman spectroscopy: Zavaleta and colleagues provide an overview of the development and applications of this novel optical technology in molecular imaging, from in vitro studies to preclinical, clinical, and future capabilities.Page 1839

Reassessing pediatric imaging: Zanzonico offers perspective on elements involved in balancing the benefits of advanced imaging techniques against risks of radiation exposure in young patients and previews a related article in this issue of JNM.Page 1845

Plaque imaging with ¹¹C-acetate: Derlin and colleagues examine the distribution and topographic relationship of ¹¹C-acetate uptake and vascular calcification in major arteries in preparation for PET/CT imaging of fatty acid synthesis in atherosclerotic vessel walls.Page 1848

PET/CT in thyroid cancer: Kauhanen and colleagues compare the abilities of ¹⁸F-DOPA and ¹⁸F-FDG PET/CT with those of MRI in localization of metastatic disease in recurrent or persistent medullary thyroid cancer.Page 1855

⁶⁸Ga-DOTATATE vs. ⁶⁸Ga-DOTATOC: Poeppel and colleagues evaluate the comparative utility of PET lesion detection with these radiolabeled somatostatin analogs in the same group of patients with neuroendocrine tumors.Page 1864

¹⁸F-FDG and ¹⁸F-FLT PET in lung cancer: Kahraman and colleagues explore the prediction of clinical benefit from first-line erlotinib treatment using different quantitative parameters for both ¹⁸F-FDG and ¹⁸F-fluorothymidine PET in advanced non–small cell lung cancer.Page 1871

Antibody–antigen relationships for huA33: O'Donoghue and colleagues use PET to analyze the quantitative features of antibody–antigen interactions in tumors and normal tissue after administration of ¹²⁴I-labeled antitumor antibodies to patients with colorectal cancer.Page 1878

sst₂ antagonist vs. agonist binding: Cescato and colleagues assess in vitro binding of the ¹⁷⁷Lu-DOTA-Bass somatostatin receptor antagonist and the ¹⁷⁷Lu-DOTATATE agonist to a range of sst₂-expressing human tumor samples.Page 1886

Arm motion and PET/CT: Lodge and colleagues investigate the mechanisms that underlie arm motion–induced cold artifacts on whole-body PET/CT images and propose a potential solution.Page 1891

¹⁸F-FLT PET in MCL: Herrmann and colleagues report on the ability of this in vivo proliferation marker to characterize mantle cell lymphoma and discuss its promise in clinical management.Page 1898

Imaging in sarcoma: Eary and Conrad offer an educational overview of ¹⁸F-FDG PET in sarcoma diagnosis and treatment response and highlight new areas of biologically specific PET techniques with potential for outcome stratification.Page 1903

Biograph mMR performance: Delso and colleagues assess the performance of a new integrated whole-body PET/MR scanner during independent and simultaneous acquisition of PET and MR data.Page 1914

Risk and benefit in pediatric imaging: Sgouros and colleagues describe a rigorous and critical approach to balancing the benefits of adequate image quality against radiation risks in children, using an example based in ^99mTc-DMSA scanning.Page 1923

Fast 3D dosimetry for ⁹⁰Y-microspheres: Dieudonné and colleagues develop and evaluate a novel approach to standardized prescribed activity calculation in selective internal radiation therapy and highlight the potential value of 3D treatment planning strategies.Page 1930

Radionuclide therapy in ovarian cancer: Zacchetti and colleagues assess the preclinical specificity of a ¹³¹I-labeled human antibody fragment that binds to folate receptors in ovary cancer cells and investigate its therapeutic efficacy in tumor models.Page 1938

PET imaging of glutaminolysis: Lieberman and colleagues report on both in vitro and in vivo animal studies with ¹⁸F-(2S,4R)4-fluoroglutamine and detail its potential use as an alternative PET tracer for mapping glutaminolytic tumors.Page 1947

Imaging angiogenesis: Liu and colleagues detail the development of a novel ⁶⁴Cu-labeled nanoprobe that detects upregulation of natriuretic peptide clearance receptors and offers sensitive detection with PET during development of angiogenesis in a mouse model.Page 1956

PET and gastric aromatase: Ozawa and colleagues use ¹¹C-vorozole PET to investigate gastric aromatase expression, which has been implicated in pathophysiologic states in various diseases via estrogen expression.Page 1964

Bombesin antagonist for prostate imaging: Abiraj and colleagues detail the development of clinically translatable bombesin antagonist–based radioligands for SPECT and PET of gastrin-releasing peptide receptor–positive tumors.Page 1970

Cell-penetrating integrin α₂β₁ probe: Huang and colleagues report on studies designed to improve the targeting efficacy of the DGEA peptide for near-infrared fluorescence and microPET imaging of integrin α₂β₁ expression in prostate cancers.Page 1979

Semiquantitative stroke imaging in rats: Ceulemans and colleagues validate the use of ^99mTc-HMPAO micro-SPECT/CT for semiquantification of infarct size after experimental stroke in rats.Page 1987

Development, sex, and cardiac risk: Guiducci and colleagues explore in minipigs the lifetime influence of innate factors, including mother's metabolism and sex of offspring, on cardiometabolic risk, including organ-specific insulin resistance, subclinical cardiac dysfunction, and DNA oxidative damage.Page 1993

⁸⁹Zr-fresolimumab PET: Oude Munnink and colleagues use radiolabeled fresolimumab, which neutralizes all mammalian forms of transforming growth factor-β, to analyze the growth factor's expression, antibody tumor uptake, and organ distribution in hamster models of human breast cancer.Page 2001

Advances in Cerenkov techniques: Xu and colleagues review the physics, cross-validations, and wide range of potential applications of Cerenkov luminescence imaging and highlight recent technical advances.Page 2009

ON THE COVER

The recently released Biograph mMR is the first commercially available integrated whole-body PET/MR scanner. It has been shown to compare favorably with other state-of-the-art PET/CT and PET/MR scanners, indicating that the integration of the PET detectors in the MR scanner and their operation within the magnetic field do not have a perceptible impact on overall performance.See page 1921.

• © 2011 by Society of Nuclear Medicine